| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2018 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APPLIED THERAPEUTICS INC | 3 | Q2 2024 | 24.2% |
| TSCAN THERAPEUTICS INC | 3 | Q2 2024 | 10.1% |
| MADRIGAL PHARMACEUTICALS INC | 3 | Q2 2024 | 7.8% |
| PHATHOM PHARMACEUTICALS INC | 3 | Q2 2024 | 5.8% |
| AKERO THERAPEUTICS INC | 3 | Q2 2024 | 5.0% |
| FULCRUM THERAPEUTICS INC | 3 | Q2 2024 | 4.2% |
| ARDELYX INC | 3 | Q2 2024 | 4.4% |
| AVIDITY BIOSCIENCES INC | 3 | Q2 2024 | 4.7% |
| ATHIRA PHARMA INC | 3 | Q2 2024 | 3.0% |
| TELESAT CORP | 3 | Q2 2024 | 2.5% |
View Propel Bio Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-08-12 |
| SC 13G | 2024-05-17 |
| 13F-HR | 2024-05-13 |
| SC 13G/A | 2024-02-22 |
| 13F-HR | 2024-02-14 |
| SC 13D/A | 2023-11-03 |
| SC 13D | 2023-10-20 |
| SC 13G/A | 2023-09-28 |
| SC 13G | 2023-08-15 |
| SC 13G | 2023-05-02 |
View Propel Bio Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.